Form 144 signals intent to sell, not a completed transaction. The small dollar amount relative to market cap and routine nature (post-RSU vesting) make this a neutral event. No immediate trading signal; monitor for any follow-on Form 4 filings to confirm execution.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 4 $22.67entry
- T+1 · 6mo ago +0.35%α +2.95% · $22.75
- T+5 · 5mo ago +3.04%α +5.60% · $23.36
- T+20 · 4mo ago +12.00%α +13.37% · $25.39
- T+60 · 3mo ago +13.63%α +11.75% · $25.76
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kristen Williams, an officer of Pacira BioSciences, filed a Form 144 intent to sell 10,259 shares of common stock, valued at approximately $228,468 based on a June 4, 2026 market price of $22.28. The shares were acquired through restricted stock vesting on June 3, 2026, as compensation. The sale is a routine post-vesting monetization by an officer, representing a small fraction of the company's $878M market cap, and does not signal material insider concern.
Key Facts
- Officer Kristen Williams filed Form 144 to sell 10,259 shares of PCRX common stock
- Proceeds estimated at ~$228,468 based on filing date price (~$22.28/share)
- Shares acquired via restricted stock vesting on June 3, 2026 (compensation)
- Sale executed through Fidelity Brokerage Services LLC
- Company market cap ~$878M; proposed sale ~0.026% of outstanding shares
- Reporting owner is an officer of Pacira BioSciences
Financial Impact
Proposed sale of ~$228K in shares, ~0.026% of market cap, immaterial
Risk Factors
- Insider could still execute the sale, but magnitude is too small to affect stock
- No material negative signal from an officer selling RSU shares for cash
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-004324 |
| Document: 0001959173-26-004324-index.html | 0001959173-26-004324 |
| Document: 0001959173-26-004324.txt | 0001959173-26-004324 |
Track record
29 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers